Vladimir Chulanov - Central Research Institute

P134 Efficacy and safety of 48-week off-therapy of Bulevirtide in combination with pegylated interferon alfa-2a in patients with chronic hepatitis delta final results from the phase 2b, open-label, randomised, multicentre study MYR204 (2024)

Cited0Views0Bibtex

Biomimetic Nanoparticles for Basic Drug Delivery

Andrey Tikhonov, Artyom Kachanov, Alexandra Yudaeva, Oleg Danilik, Natalia Ponomareva, Ivan Karandashov, Anastasiya Kostyusheva, Andrey A Zamyatnin, Alessandro Parodi,Vladimir Chulanov,Sergey Brezgin, Dmitry Kostyushev

Pharmaceuticsno. 10 (2024)

Cited0Views0WOSBibtex

Bulevirtide Monotherapy in Patients with Chronic HDV: Efficacy and Safety Results Through Week 96 from a Phase III Randomized Trial

JOURNAL OF HEPATOLOGYno. 4 (2024)

Cited0Views0WOSBibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn